Viridian Therapeutics, Inc.\DE (VRDN) Accounts Payables (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Accounts Payables history runs 14 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 242.59% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 242.59% increase from a year earlier, with the FY2025 full-year figure at $8.7 million, up 305.18% from the prior year.
• Accounts Payables grew to $13.3 million in Q1 2026 per VRDN's latest filing, from $8.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.2 million in Q4 2022 and bottomed at $2.1 million in Q4 2024.
• The 5-year median for Accounts Payables is $4.1 million (2023), against an average of $6.5 million.
• Across the five-year window, Accounts Payables soared 511.16% in 2022 and sank 84.27% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $14.2 million in 2022, then sank by 84.27% to $2.2 million in 2023, then declined by 4.29% to $2.1 million in 2024, then soared by 305.18% to $8.7 million in 2025, then jumped by 53.32% to $13.3 million in 2026.
• Per Business Quant, the three latest VRDN Accounts Payables figures stand at $13.3 million (Q1 2026), $8.7 million (Q4 2025), and $10.1 million (Q3 2025).